US 12,103,966 B2
GRP78-binding antibodies and uses thereof in detecting or neutralizing GRP78
Renata Pasqualini, New Brunswick, NJ (US); Wadih Arap, New Brunswick, NJ (US); Fernanda Iamassaki Staquicini, New Brunswick, NJ (US); Fortunato Ferrara, Santa Fe, NM (US); Sara D'Angelo, Santa Fe, NM (US); and Andrew R. M. Bradbury, Santa Fe, NM (US)
Assigned to Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed by Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed on Jun. 10, 2022, as Appl. No. 17/837,888.
Application 17/592,828 is a division of application No. 16/333,898, granted, now 11,254,751, previously published as PCT/US2017/052661, filed on Sep. 21, 2017.
Application 17/837,888 is a continuation of application No. 17/592,828, filed on Feb. 4, 2022.
Claims priority of provisional application 62/397,521, filed on Sep. 21, 2016.
Claims priority of provisional application 62/397,512, filed on Sep. 21, 2016.
Prior Publication US 2022/0348680 A1, Nov. 3, 2022
Int. Cl. C07K 16/18 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); A61K 38/07 (2006.01); A61K 39/00 (2006.01); A61K 49/00 (2006.01); C07K 14/47 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12N 15/10 (2006.01); C12N 15/64 (2006.01); C12Q 1/6869 (2018.01); G01N 33/50 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/6803 (2017.08); A61K 47/68031 (2023.08); A61K 47/68033 (2023.08); A61P 35/00 (2018.01); C07K 16/30 (2013.01); C07K 16/3023 (2013.01); G01N 33/574 (2013.01); A61K 38/07 (2013.01); A61K 2039/505 (2013.01); A61K 47/6817 (2017.08); A61K 47/6843 (2017.08); A61K 47/6849 (2017.08); A61K 47/6891 (2017.08); A61K 49/0008 (2013.01); C07K 14/47 (2013.01); C07K 16/005 (2013.01); C07K 16/28 (2013.01); C07K 16/2866 (2013.01); C07K 2317/21 (2013.01); C07K 2317/35 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C12N 15/1037 (2013.01); C12N 15/64 (2013.01); C12N 2810/00 (2013.01); C12Q 1/6869 (2013.01); G01N 33/5011 (2013.01); G01N 33/57423 (2013.01)] 26 Claims
 
1. An isolated monoclonal antibody, wherein the antibody specifically binds to GRP78 (78 kDa glucose-regulated protein) and comprises:
a heavy chain variable region (VH) comprising a VH CDR1 having the amino acid sequence set forth in SEQ ID NO: 39, a VH CDR2 having the amino acid sequence set forth in SEQ ID NO: 40, and a VH CDR3 having the amino acid sequence set forth in SEQ ID NO: 41;
and
a light chain variable region (VL) comprising a VL CDR1 having the amino acid sequence set forth in SEQ ID NO: 42, a VL CDR2 having the amino acid sequence set forth in SEQ ID NO: 43, and a VL CDR3 having the amino acid sequence set forth in SEQ ID NO: 44.